Entrada Therapeutics Inc (TRDA) — Titan Protect Analysis

TRDA

Entrada Therapeutics Inc

Healthcare · ·

$6.37

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$257M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-1.94

Based on estimated future earnings — lower means cheaper

Rev Growth

-95.7%

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-48.3%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$21.50

+238% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 4 analysts covering this stock

About Entrada Therapeutics Inc

Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-

https://www.entradatx.com

Country: United States Employees: 152 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

-0.152

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0279

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.453

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-34.8%

Historical annualised return based on price data

Max Drawdown

-76.8%

Largest peak-to-trough decline — the worst it has been

HMM State

BULL

Statistical model sees bullish momentum

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

-0.09

Very low correlation to market moves

52W High

$16.45

61% below the year high

52W Low

$4.93

29% above the year low

Avg Volume

364,238

Average daily shares traded — higher means easier to buy and sell

Short Ratio

2.7

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-4.00

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

18.37

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

-4,834.6%

Profit from core operations before interest and tax

Free Cash Flow

$-75,381,376

Negative — the business is spending more than it generates

Revenue (TTM)

$6M

Total revenue over the last 12 months

Net Income

$-166,118,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$25.00

Target Median

$21.50

Target Low

$10.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go